Yuvezzi (carbachol/brimonidine tartrate)
Parasympathetic Miotics Ophthalmic (Eye) Dropperette, Single-Use Drop Dispenser
Last reviewed · Source: First Databank (FDB) drug data
Overview
Carbachol and brimonidine tartrate (carbachol/brimonidine) is a fixed-combination preparation containing carbachol (a cholinergic agonist) andbrimonidine (an alpha-adrenergic receptor agonist).
USES: This medication is used to treat age-related farsightedness (presbyopia). This product contains 2 medications: carbachol and brimonidine. They work together by causing the pupil of the eye to shrink, which may help with seeing things up close.
Generic name: carbachol/brimonidine tartrate
Pronunciation: (KAR-ba-kol/bri-MOE-ni-deen)
Drug class: Parasympathetic Miotics
Therapeutic class: Ophthalmic Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Yuvezzi
Indications
The following indications are listed for Yuvezzi:
- Presbyopia
Dosing
*The recommended dosage of carbachol/brimonidine is one drop in each eye once daily.
*Remove contact lenses prior to instillation of carbachol/brimonidine. Wait 10 minutes after dosing before reinserting contact lenses.
*If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.
*One single-dose vial can be used to dose both eyes. Discard the open single-dose vial and any remaining contents immediately after use.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Yuvezzi 2.75%-0.1% Eye Drop | Maintenance | Instill 1 drop into both eyes by ophthalmic route once daily. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
*Patients with known hypersensitivity to the active ingredients or to any of the excipients.
- Iritis
There are no severe contraindications for this drug.
- Buerger's disease
- Cerebrovascular disorder
- Coronary artery disease
- Depression
- Orthostatic hypotension
- Raynaud's phenomenon
- Retinal detachment
Adverse reactions
Most common adverse reactions (incidence >5%) are eye pain upon instillation, visual impairment, eye irritation upon instillation, and headache.
More Frequent
- Conjunctival hyperemia
- Follicular conjunctivitis
- Headache disorder
- Ocular itching
- Ocular redness
Less Frequent
- Blepharitis
- Blurred vision
- Chemosis
- Chest pain
- Conjunctival hemorrhage
- Corneal erosion
- Depression
- Diabetes mellitus
- Dizziness
- Eyelid edema
- Gastrointestinal irritation
- Hypertension
- Mucopurulent conjunctivitis
- Myalgia
- Nasal congestion
- Nausea
- Ocular discomfort
- Ocular pain
- Rhinitis
- Sneezing
- Syncope
- Visual changes
- Vitreous detachment
- Vomiting
Rare or Very Rare
- Asthma
- Bradycardia
- Bullous keratopathy
- Cardiac arrhythmia
- Corneal edema
- Hypotension
- Increased urinary frequency
- Iritis
- Ocular hypertension
- Retinal detachment
- Syncope
More Frequent
- Allergic conjunctivitis
- Blurred vision
- Drowsy
- Eye tearing
- Fatigue
- Ocular irritation
- Ocular pain
- Visual changes
- Xerostomia
Less Frequent
- Acute abdominal pain
- Arthralgia
- Arthritis
- Blepharoconjunctivitis
- Blepharospasm
- Bronchitis
- Cataracts
- Conjunctival blanching
- Conjunctivitis
- Corneal staining
- Cough
- Dry eye
- Dysgeusia
- Dyspepsia
- Dyspnea
- Eyelid crusting
- Eyelid erythema
- Foreign body sensation of eye
- General weakness
- Headache disorder
- Hypercholesterolemia
- Hypotension
- Infection
- Insomnia
- Keratitis
- Muscle weakness
- Ocular discharge
- Ocular hypertension
- Ocular irritation
- Osteoporosis
- Palpitations
- Pharyngitis
- Photophobia
- Sinusitis
- Skin rash
- Symptoms of anxiety
- Visual field defect
- Vitreous floater
Rare or Very Rare
- Abdominal pain with cramps
- Bladder irritability
- Corneal opacity
- Diarrhea
- Dry nose
- Dyspepsia
- Flushing
- Hyperhidrosis
- Iritis
- Nausea
- Ocular inflammation
- Ocular redness
- Vomiting
Precautions
No enhanced messaging available.
Presbyopia does not occur in the pediatric population.
There are no adequate and well-controlled studies of carbachol/brimonidine administration in pregnant women to inform a drug-associated risk. Topical ocular administration of carbachol/brimonidine to pregnant rats throughout organogenesis did not produce adverse effects up to 3 times the maximum recommended human ocular dose (MRHOD). Topical ocular administration of carbachol/brimonidine to pregnant rabbits throughout organogenesis at approximately 3 times the MRHOD resulted in maternal toxicity with no effect on the fetus, including reduced maternal food consumption, body weight change, and related moribundity in 2/25 animals during the dosing period. Body weight and food consumption effects recovered after the dosing stopped. Because animal reproductive studies are not always predictive of human response, carbachol/brimonidine should be administered during pregnancy only if the potential benefit justifies the potential risk to the pregnant mother and fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.
There is no information regarding the presence of carbachol/brimonidine in human milk, the effects on the breastfed infants, or the effects on milk production to inform risk of carbachol/brimonidine to an infant during lactation. Systemic levels of carbachol and brimonidine tartrate following topical ocular administration of carbachol/brimonidine are low, and it is not known whether measurable levels of carbachol and brimonidine tartrate would be present in maternal milk following topical ocular administration. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for carbachol and brimonidine and any potential adverse effects on the breastfed child from the drugs.
No overall differences in safety or effectiveness have been observed between elderly and adult patients.
ICD codes
| Code | Type | Description |
|---|---|---|
| Presbyopia | ||
| H52.4 | ICD10CM | Presbyopia |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.